June 2, 2025 – Sanofi on Monday announced plans to acquire the United States-based biotech company Blueprint Medicines Corporation. This initiative is intended to expand Sanofi’s portfolio in rare immunological diseases as well as add an early-stage pipeline in immunology.
The deal includes a cash offer of $129 per share, plus up to $6 per share in milestone-based contingent value rights (CVRs), potentially bringing the total value to approximately $9.5 billion. This acquisition would be Europe's biggest healthcare deal in 2025.
The acquisition includes Ayvakit/Ayvakyt (avaprintinib), a rare immunology disease medicine approved in both the US and EU. It also encompasses a promising pipeline of advanced early-stage immunology candidates.
Ayvakit/Ayvakyt is the only approved medicine for both advanced systemic mastocytosis (ASM) and indolent systemic mastocytosis (ISM). This rare immunological disorder is marked by the buildup and activation of abnormal mast cells in the bone marrow as well as skin, gastrointestinal tract, and other organs.
The acquisition will also include elenestinib, a next-generation medicine for systemic mastocytosis. Additionally, it will bring BLU-808, a highly selective and potent oral inhibitor of wild-type KIT. BLU-808 has the potential to treat a wide range of diseases in immunology.
Views and Statements
In the words of Paul Hudson, Sanofi’s CEO, “The proposed acquisition of Blueprint Medicines advances our rare and immunology portfolios. It boosts our pipeline and accelerates our goal to lead in immunology.”
The acquisition aligns with Sanofi’s strategy to strengthen key areas, deliver differentiated medicines, and generate strong shareholder returns. It complements the company’s recent early-stage acquisitions.
Hudson further added, “We’re excited to welcome Blueprint’s team and collaborate on scientific breakthroughs together. This collaboration will benefit science as well as both companies, healthcare professionals, and most importantly, patients.”
Speaking on the occasion, Kate Haviland, CEO of Blueprint Medicine, said, “This agreement marks the beginning of our next chapter with Sanofi, a leader in rare diseases and immunology. Their proven ability to address medical challenges at scale will help us accelerate our shared mission to deliver life-changing medicines to more patients worldwide.”
Impact and Future Outlook
Sanofi’s $9.5 billion acquisition of Blueprint Medicines marks a pivotal moment in the biopharma landscape. It represents not only Europe’s largest healthcare deal of 2025 but also a strategic leap forward in the treatment of rare immunological diseases.
By acquiring Blueprint's portfolio, including the only approved treatment for systemic mastocytosis and a strong pipeline of early-stage immunology candidates, Sanofi significantly strengthens its position in specialty care and rare diseases. This move enhances its R&D capabilities and reinforces its ambition to lead in immunology.
Looking ahead, the deal is expected to accelerate innovation, broaden patient access to novel therapies, and generate substantial long-term value for shareholders. It will also encourage other pharmaceutical companies to increase their investment in developing novel rare disease drugs.
Blueprint Medicines’ acquisition also highlights the rising trend of employing inorganic strategies in the rare disease drugs industry. Other companies are expected to follow Sanofi’s suit by advancing rare disease treatments through acquisitions and collaborations.
Sources:
News Outlet: Reuters
Company: Sanofi
